Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) EBIT: 2019-2024

Historic EBIT for Compass Therapeutics (CMPX) over the last 6 years, with Dec 2024 value amounting to -$56.6 million.

  • Compass Therapeutics' EBIT fell 29.23% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$71.4 million, marking a year-over-year decrease of 28.81%. This contributed to the annual value of -$56.6 million for FY2024, which is 12.43% down from last year.
  • As of FY2024, Compass Therapeutics' EBIT stood at -$56.6 million, which was down 12.43% from -$50.4 million recorded in FY2023.
  • In the past 5 years, Compass Therapeutics' EBIT registered a high of -$32,105 during FY2020, and its lowest value of -$81.9 million during FY2021.
  • Moreover, its 3-year median value for EBIT was -$50.4 million (2023), whereas its average is -$49.5 million.
  • As far as peak fluctuations go, Compass Therapeutics' EBIT tumbled by 194.41% in 2021, and later soared by 49.13% in 2022.
  • Yearly analysis of 5 years shows Compass Therapeutics' EBIT stood at -$32,105 in 2020, then rose by 18.32% to -$27.8 million in 2020, then plummeted by 194.41% to -$81.9 million in 2021, then spiked by 49.13% to -$41.7 million in 2022, then decreased by 20.91% to -$50.4 million in 2023, then declined by 12.43% to -$56.6 million in 2024.